New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
08:17 EDTMSTXMast Therapeutics agrees to acquire Aires Pharmaceuticals
Mast Therapeutics announced that it has entered into a definitive agreement to acquire Aires Pharmaceuticals, a clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure. Aires' lead product, AIR001, is an intermittently nebulized formulation of nitrite and has orphan drug status with the FDA and the EMA for the treatment of pulmonary arterial hypertension. Under the terms of the all-stock transaction, Aires would become a wholly-owned subsidiary of Mast Therapeutics. The acquisition is expected to close in February 2014, subject to customary closing conditions.
News For MSTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
08:10 EDTMSTXMast Therapeutics to present new data from nonclinical heart failure study
Subscribe for More Information
November 17, 2014
10:02 EDTMSTXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTMSTXMast Therapeutics to present MST-188 data at conference
Subscribe for More Information
07:38 EDTMSTXMast Therapeutics re-initiated with a Buy at Canaccord
Target $3.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use